{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:59:43Z","timestamp":1791046783345,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2003,7,1]],"date-time":"2003-07-01T00:00:00Z","timestamp":1057017600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2003,7]]},"DOI":"10.1038\/sj.bjc.6601105","type":"journal-article","created":{"date-parts":[[2003,7,15]],"date-time":"2003-07-15T17:14:20Z","timestamp":1058289260000},"page":"262-267","source":"Crossref","is-referenced-by-count":56,"title":["Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane"],"prefix":"10.1038","volume":"89","author":[{"given":"H","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J T","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M P","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Propper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A L","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2003,7,15]]},"reference":[{"key":"BF6601105_CR1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/00006231-200202000-00004","volume":"23","author":"H Anderson","year":"2002","unstructured":"Anderson H, Price P (2002) Blood flow in tumours using PET: a review. Nucl Med Commun 23: 131\u2013138","journal-title":"Nucl Med Commun"},{"key":"BF6601105_CR2","doi-asserted-by":"crossref","unstructured":"Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM (2003) Assessment of pharmacodynamic vascular response in a Phase I Trial of combretastatin A4 phosphate. J Clin Oncol (in press)","DOI":"10.1200\/JCO.2003.05.186"},{"key":"BF6601105_CR3","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1161\/01.CIR.83.3.875","volume":"83","author":"LI Araujo","year":"1991","unstructured":"Araujo LI, Lammerstma AA, Rhodes CG, McFalls EO, Iida H, Rechavia E, Galassi A . De Silva R, Jones T, Maseri A (1991) Noninvasive quantification of regional myocardial blood flow in coronary artery disease with oxygen-15-labeled carbon dioxide inhalation and positron emission tomography. Circulation 83: 875\u2013885","journal-title":"Circulation"},{"key":"BF6601105_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0305-7372(76)80007-2","volume":"3","author":"MT Bakowski","year":"1976","unstructured":"Bakowski MT (1976) ICRF 159, (+\/\u2212) 1,2-di(3,5-dioxopiperazin-1-yl) propane NSC-129,943; razoxane. Cancer Treat Rev 3: 95\u2013107","journal-title":"Cancer Treat Rev"},{"key":"BF6601105_CR5","first-page":"1395","volume":"60","author":"RE Bellet","year":"1976","unstructured":"Bellet RE, Engstrom PF, Catalano RB, Creech RH, Mastrangelo MJ (1976) Phase II study of ICRF-159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy. Cancer Treat Rep 60: 1395\u20131397","journal-title":"Cancer Treat Rep"},{"key":"BF6601105_CR6","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/ijc.1471","volume":"94","author":"AS Boehle","year":"2001","unstructured":"Boehle AS, Kurdow R, Schulze M, Kliche U, Sipos B, Soondrum K, Ebrahimnejad A, Dohrmann P, Kalthoff H, Henne-Bruns D, Neumaier M (2001) Human endostatin inhibits growth of human non-small-cell lung cancer in a murine xenotransplant model. Int J Cancer 94: 420\u2013428","journal-title":"Int J Cancer"},{"key":"BF6601105_CR7","first-page":"4697","volume":"6","author":"JP Braybrooke","year":"2000","unstructured":"Braybrooke JP, O'Byrne KJ, Propper DJ, Blann A, Saunders M, Dobbs N, Han C, Woodhull J, Mitchell K, Crew J, Smith K, Stephens R, Ganesan TS, Talbot DC, Harris AL (2000) A Phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of antiangiogenesis. Clin Cancer Res 6: 4697\u20134704","journal-title":"Clin Cancer Res"},{"key":"BF6601105_CR8","first-page":"1255","volume":"143","author":"LF Brown","year":"1993","unstructured":"Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR (1993) Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 143: 1255\u20131262","journal-title":"Am J Pathol"},{"key":"BF6601105_CR9","first-page":"1294","volume-title":"Campbell's Urology","author":"JB DeKernion","year":"1986","unstructured":"DeKernion JB (1986) Renal tumors. In Campbell's Urology, Walsh PC, Gittes RF, Perlmutter AD (eds) pp 1294\u20131342. Philadelphia: W.B. Saunders"},{"key":"BF6601105_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/224273a0","volume":"224","author":"K Hellmann","year":"1969","unstructured":"Hellmann K, Burrage K (1969) Control of malignant metastases by ICRF l59. Nature 224: 273\u2013275","journal-title":"Nature"},{"key":"BF6601105_CR11","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1200\/JCO.2002.05.102","volume":"20","author":"RS Herbst","year":"2002","unstructured":"Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O'Reilly MS, Kim H-W, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL (2002) Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 20: 3804\u20133814","journal-title":"J Clin Oncol"},{"key":"BF6601105_CR12","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1259\/0007-1285-58-692-725","volume":"58","author":"AA Lammertsma","year":"1985","unstructured":"Lammertsma AA, Wise RJ, Cox TC, Thomas DG, Jones T (1985) Measurement of blood flow, oxygen utilisation, oxygen extraction ratio, and fractional blood volume in human brain tumours and surrounding oedematous tissue. Br J Radiol 58: 725\u2013734","journal-title":"Br J Radiol"},{"key":"BF6601105_CR13","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1136\/bmj.1.5800.597","volume":"4","author":"AW Le Serve","year":"1972","unstructured":"Le Serve AW, Hellmann K (1972) Metastases and the normalization of tumour blood vessels by ICRF 159: a new type of drug action. BMJ 4: 597\u2013601","journal-title":"BMJ"},{"key":"BF6601105_CR14","first-page":"500","volume":"43","author":"DA Mankoff","year":"2002","unstructured":"Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, Schubert EK, Tseng J, Livingston RB (2002) Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 43: 500\u2013509","journal-title":"J Nucl Med"},{"key":"BF6601105_CR15","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/1097-0215(20000901)87:5<650::AID-IJC5>3.0.CO;2-3","volume":"87","author":"AJ Meyer","year":"2000","unstructured":"Meyer AJ, Hernandez A, Florl AR, Enczmann J, Gerharz CD, Schulz WA, Wernet P, Ackermann R (2000) Novel mutations of the von Hippel\u2013Lindau tumor-suppressor gene and rare DNA hypermethylation in renal-cell carcinoma cell lines of the clear-cell type. Int J Cancer 87: 650\u2013653","journal-title":"Int J Cancer"},{"key":"BF6601105_CR16","first-page":"1355","volume":"64","author":"MJ O'Connell","year":"1980","unstructured":"O'Connell MJ, Begg CB, Silverstein MN, Glick JH, Oken MM (1980) Randomized clinical trial comparing two dose regimens of ICRF-159 in refractory malignant lymphomas. Cancer Treat Rep 64: 1355\u20131358","journal-title":"Cancer Treat Rep"},{"key":"BF6601105_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1357-4310(99)01481-1","volume":"5","author":"M Ohh","year":"1999","unstructured":"Ohh M, Kaelin WG (1999) The von Hippel\u2013Lindau tumour suppressor protein: new perspectives. Mol Med Today 5: 257\u2013263","journal-title":"Mol Med Today"},{"key":"BF6601105_CR18","first-page":"259","volume":"17","author":"AS Ranicar","year":"1991","unstructured":"Ranicar AS, Williams CW, Schnorr L, Clark JC, Rhodes CG, Bloomfield PM, Jones T (1991) The on-line monitoring of continuously withdrawn arterial blood during PET studies using a BGO\/photomultiplier assembly and non-stick tubing. Med Prog Technol 17: 259\u2013264","journal-title":"Med Prog Technol"},{"key":"BF6601105_CR19","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1136\/bmj.4.5731.344","volume":"4","author":"AJ Salsbury","year":"1970","unstructured":"Salsbury AJ, Burrage K, Hellmann K (1970) Inhibition of metastatic spread by I.C.R.F. 159: selective deletion of a malignant characteristic. BMJ 4: 344\u2013346","journal-title":"BMJ"},{"key":"BF6601105_CR20","first-page":"843","volume":"34","author":"AJ Salsbury","year":"1974","unstructured":"Salsbury AJ, Burrage K, Hellmann K (1974) Histological analysis of the antimetastatic effect of (plus or minus)-1,2-bis(3,5-dioxopiperazin-1-yl)propane. Cancer Res 34: 843\u2013849","journal-title":"Cancer Res"},{"key":"BF6601105_CR21","first-page":"1032","volume":"87","author":"R Sasaki","year":"1996","unstructured":"Sasaki R (1996) Microvessel count and vascular endothelial growth factor in renal cell carcinoma. Nippon Hinyokika Gakkai Zasshi 87: 1032\u20131040","journal-title":"Nippon Hinyokika Gakkai Zasshi"},{"key":"BF6601105_CR22","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/226524a0","volume":"226","author":"HB Sharpe","year":"1970","unstructured":"Sharpe HB, Field EO, Hellmann K (1970) Mode of action of the cytostatic agent \u2018ICRF 159\u2019. Nature 226: 524\u2013526","journal-title":"Nature"},{"key":"BF6601105_CR23","first-page":"1522","volume":"37","author":"H Taniguchi","year":"1996","unstructured":"Taniguchi H, Koyama H, Masuyama M, Takada A, Mugitani T, Tanaka H, Hoshima M, Takahashi T (1996) Angiotensin-II-induced hypertension chemotherapy: evaluation of hepatic blood flow with oxygen-15 PET. J Nucl Med 37: 1522\u20131523","journal-title":"J Nucl Med"},{"key":"BF6601105_CR24","first-page":"2472","volume":"32A","author":"PB Vermeulen","year":"1996","unstructured":"Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL, Dirix LY (1996) Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A: 2472\u20132484","journal-title":"Eur J Cancer"},{"key":"BF6601105_CR25","first-page":"1592","volume":"52","author":"CB Wilson","year":"1992","unstructured":"Wilson CB, Lammertsma AA, McKenzie CG, Sikora K, Jones T (1992) Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. Cancer Res 52: 1592\u20131597","journal-title":"Cancer Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6601105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6601105","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6601105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:51:10Z","timestamp":1684414270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6601105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,7]]}},"alternative-id":["BF6601105"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6601105","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7]]}}}